Avantax Advisory Services Inc. Has $2.15 Million Stake in ADMA Biologics Inc (NASDAQ:ADMA)

Avantax Advisory Services Inc. grew its position in ADMA Biologics Inc (NASDAQ:ADMA) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,327 shares of the biotechnology company’s stock after purchasing an additional 1,954 shares during the quarter. Avantax Advisory Services Inc.’s holdings in ADMA Biologics were worth $2,149,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company’s stock valued at $13,159,000 after purchasing an additional 561,310 shares during the last quarter. New York State Teachers Retirement System grew its position in shares of ADMA Biologics by 96.2% in the first quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company’s stock valued at $4,402,000 after purchasing an additional 108,800 shares during the last quarter. GAMMA Investing LLC grew its position in shares of ADMA Biologics by 251.6% in the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 4,715 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in ADMA Biologics during the first quarter worth approximately $201,000. Finally, Ameriprise Financial Inc. grew its position in ADMA Biologics by 14.1% during the fourth quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company’s stock worth $12,274,000 after buying an additional 88,542 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ADMA. Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Raymond James Financial increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research report on Thursday, May 8th.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the firm’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company’s stock, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the firm’s stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 464,621 shares of company stock valued at $9,644,269. 3.50% of the stock is currently owned by corporate insiders.

ADMA Biologics Trading Up 1.8%

Shares of NASDAQ:ADMA opened at $18.59 on Thursday. The company has a market capitalization of $4.44 billion, a P/E ratio of 21.87 and a beta of 0.43. ADMA Biologics Inc has a 1 year low of $10.21 and a 1 year high of $25.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The business’s 50 day simple moving average is $18.86 and its 200 day simple moving average is $18.72.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company’s revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.08 EPS. On average, research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.